A drug combination containing a TLR7 agonist. Specifically, a drug combination jointly using the compound of formula I acting as a TLR7 agonist and entecavir for the treatment of hepatitis B virus infection and a use thereof, the drug combination having a good anti-hepatitis B virus infection effect.

##STR00001##

A drug combination containing a TLR7 agonist. Specifically, a drug combination jointly using the compound of formula I acting as a TLR7 agonist and entecavir for the treatment of hepatitis B virus infection and a use thereof, the drug combination having a good anti-hepatitis B virus infection effect.

##STR00001##

Disclosed herein are compositions and methods for an embolizing agent precursor. The embolizing agent precursor may include a gaseous component and a first stabilizer to stabilize the gaseous component, the first stabilizer may include a a polymer, and wherein a gas portion of the gaseous component is selected from the group consisting of sulphur hexafluoride and C3-6 perfluorocarbons. The embolizing agent precursor may further include an oil component which comprises a C1-7 hydrocarbon, a second stabilizer to stabilize the oil component, and a vaporous component configured to enlarge the gaseous component.

Disclosed herein are compositions and methods for an embolizing agent precursor. The embolizing agent precursor may include a gaseous component and a first stabilizer to stabilize the gaseous component, the first stabilizer may include a a polymer, and wherein a gas portion of the gaseous component is selected from the group consisting of sulphur hexafluoride and C3-6 perfluorocarbons. The embolizing agent precursor may further include an oil component which comprises a C1-7 hydrocarbon, a second stabilizer to stabilize the oil component, and a vaporous component configured to enlarge the gaseous component.

Provided are methods of treating cancer that comprise administering a polypeptide (e.g. a fusion polypeptide) that comprises a SIRPα D1 domain variant and an Fc domain variant in combination with at least one chemotherapy agent and/or at least one therapeutic antibody. Also provided are related kits.

Provided are methods of treating cancer that comprise administering a polypeptide (e.g. a fusion polypeptide) that comprises a SIRPα D1 domain variant and an Fc domain variant in combination with at least one chemotherapy agent and/or at least one therapeutic antibody. Also provided are related kits.

The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.

The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.

The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.

The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.